Amgen 2012 Annual Report Download - page 70

Download and view the complete annual report

Please find page 70 of the 2012 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 150

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150

63
Neulasta®/NEUPOGEN®
Total Neulasta® and total NEUPOGEN® sales by geographic region were as follows (dollar amounts in millions):
2012 Change 2011 Change 2010
Neulasta® — U.S. $ 3,207 7 % $ 3,006 13 % $ 2,654
Neulasta® — ROW 885 (6)% 946 5 % 904
Total Neulasta®4,092 4 % 3,952 11 % 3,558
NEUPOGEN® — U.S. 1,007 5 % 959 3 % 932
NEUPOGEN® — ROW 253 (16)% 301 (15)% 354
Total NEUPOGEN®1,260 — % 1,260 (2)% 1,286
Total Neulasta®/NEUPOGEN®$ 5,352 3 % $ 5,212 8 % $ 4,844
The increase in U.S. Neulasta® sales for 2012 was driven by an increase in the average net sales price. The decrease in
ROW Neulasta® sales for 2012 was due primarily to a decrease in unit demand from loss of share to biosimilars in Europe and a
decrease in the average net sales price.
The increase in U.S. NEUPOGEN® sales for 2012 was driven by an increase in the average net sales price. The decrease
in ROW NEUPOGEN® sales for 2012 was driven by a decrease in unit demand from loss of share to biosimilars in Europe.
The increase in U.S. Neulasta® sales for 2011 was driven by increases in both unit demand and the average net sales price.
The increase in ROW Neulasta® sales for 2011 was driven primarily by an increase in unit demand.
The increase in U.S. NEUPOGEN® sales for 2011 was driven by an increase in the average net sales price, offset partially
by a decrease in unit demand. The decrease in ROW NEUPOGEN® sales for 2011 was driven by a decrease in unit demand, in
part, from loss of share to biosimilars in Europe, and a decrease in the average net sales price.
Our outstanding material U.S. patents for Filgrastim (NEUPOGEN®) expire in December 2013. We expect to face
competition in the United States beginning in the fourth quarter of 2013, which may have a material adverse impact over time on
future sales of NEUPOGEN® and, in turn, Neulasta®. See Financial Condition, Liquidity and Capital Resources for further
discussion of the potential impact of patent expiration. Our outstanding material U.S. patent for pegfilgrastim (Neulasta®) expires
in 2015.
Future Neulasta®/NEUPOGEN® sales will also depend, in part, on the development of new protocols, tests and/or treatments
for cancer and/or new chemotherapy treatments or alternatives to chemotherapy that may have reduced and may continue to reduce
the use of chemotherapy in some patients.
ENBREL
Total ENBREL sales by geographic region were as follows (dollar amounts in millions):
2012 Change 2011 Change 2010
ENBREL — U.S. $ 3,967 15% $ 3,458 5% $ 3,304
ENBREL — Canada 269 11% 243 6% 230
Total ENBREL $ 4,236 14% $ 3,701 5% $ 3,534
The increase in ENBREL sales for 2012 was driven primarily by an increase in the average net sales price and, to a lesser
extent, an increase in unit demand.
The increase in ENBREL sales for 2011 was driven primarily by an increase in the average net sales price.
ENBREL also faces increased competition. See Item 1. Business — Marketed Products.